View More
Learn about the integration of biosimilars into oncology care with this expert-authored module reviewing biosimilar fundamentals, the regulatory review process for biosimilars, current FDA-approved biosimilars, and key trial data on biosimilars in breast and lung cancers.
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP
Physicians:
maximum of 1.0 AMA PRA Category 1 Credit™
Registered Nurses:
1.0 Nursing contact hour
Pharmacists:
1.0 contact hour (0.1 CEUs)
Released: April 20, 2020
Expired: April 19, 2021
Download these slides with expert recommendations on the approval and integration of oncology biosimilars for clinical practice.
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP
Released: April 20, 2020
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.